NCT01223768

Acetyl-L-Carnitine In Severe Hepatic Encephalopathy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: —
• Sponsor: University of Catania · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: —

Summary

To assess the clinical efficacy of ALC in the treatment of severe hepatic encephalopathy (grade 3 of the West Haven grading scale), we performed a randomised, double blind placebo-controlled study administering ALC to cirrhotic patients, evaluating the effects on ammonia levels and performance in cognitive functions.

Conditions

• Hepatic Encephalopathy (Grade 3 of the West Haven Grading Scale)

Interventions

Type	Name	Description
DRUG	Acetyl-l-Carnitine	2g per day
DRUG	placebo	twice per day

Timeline

• Start date: 2002-07-01
• Completion: 2005-12-01
• First posted: 2010-10-19
• Last updated: 2010-10-19

Locations

1 site across 1 country: Italy